Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases

摘要

Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition of prevention of autoimmune diseases.